pre-IPO PHARMA

COMPANY OVERVIEW

Virion Therapeutics, LLC, is a science driven company developing innovative immune-based treatments for virally-associated cancers and chronic viral infections. Our vaccines, ChiVax and ChiVax-gD, represent novel and highly effective platforms to induce potent and sustained T cell-mediated immune responses against transformed or infected cells, thereby allowing us to target common diseases with unmet medical needs. Each component comprising our chimeric vaccine candidates has completed pre-clinical testing that allow for their translation into clinical trials for a number of different indications. Guided by our scientific and management expertise, these platforms may help cure such devastating diseases as HPV-induced cancers and chronic Hepatitis B infections.


LOCATION

  • Phiadephia, PA, USA

  • THERAPEUTIC AREAS

  • Infectious Disease
  • Oncology

  • WEBSITE

    https://www.viriontx.com


    CAREER WEBSITE


    SOCIAL MEDIA


    INVESTORS

    alliance-of-angels crimson-peak ife-science-angels keiretsu-forum keiretsu-forum mid-atlantic-bio-angels-group robin-hood-ventures


    PRESS RELEASES


    Nov 17, 2020

    Virion Therapeutics Wins Prestigious 'Most Valued Company' at Keiretsu Forum Investor Capital Expo


    Oct 1, 2018

    Virion Therapeutics, LLC Announces its Inaugural Board of Directors and Scientific Advisory Board Members


    Sep 26, 2018

    Virion Therapeutics, LLC Raises $5 Million to Develop Checkpoint Inhibitor Powered Vaccine Therapies for Treatment of Virally Induced Infectious Diseases & Cancers


    Apr 28, 2017


    For More Press Releases


    Google Analytics Alternative